Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction
-
1. Psychopharmacology: structural aspects of the brain
- Prof. Brian Leonard
-
2. The nature of chemical neurotransmission
- Prof. Brian Leonard
-
3. Psychotropic drugs
- Prof. Brian Leonard
-
4. Psychopharmacology of anxiety disorders
- Prof. Brian Leonard
-
5. Psychopharmacology of depression
- Prof. Brian Leonard
-
6. Psychopharmacology of mania and schizophrenia
- Prof. Brian Leonard
-
7. The role of stress and immune system in psychiatric disorders
- Prof. Brian Leonard
- Introduction to Genetic Investigations of Complex Traits
- Genetics and Pharmacokinetics of Psychotropic Drugs
-
9. Genetics of phase I enzymes
- Prof. Aiming Yu
-
10. Phase II metabolism
- Prof. Ann Daly
- Genetics and Pharmacodynamics of Psychotropic Drugs
-
13. Pharmacogenetics of antidepressants
- Prof. Alessandro Serretti
- Clinical Applications of Psychopharmacogenetics
-
14. Of genes and drugs: genetic determinants of adverse drug reactions
- Dr. Mario Masellis
-
15. Cocaine and amphetamine addiction genetics
- Dr. Gerome Breen
- Archived Lectures *These may not cover the latest advances in the field
-
18. Genetic determinants of metabolism: clinical applications in psychiatry
- Prof. Julia Stingl (formerly Kirchheiner)
-
20. Genetic polymorphisms influencing response to lithium
- Prof. Alessandro Serretti
-
21. Genetic determinants of antipsychotic-induced weight gain
- Prof. Gavin Reynolds
-
24. Genetic determinants of agranulocytosis
- Dr. Michael Dettling
-
25. Genetic polymorphisms influencing the response of antidepressants
- Prof. Alessandro Serretti
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Inter-patient variations in drug therapy
- Variations in phase I metabolism
- Causes of inter-patient variations
- Phase I drug-metabolizing enzymes
- Genetics of human CYP enzymes
- Genetic polymorphism of CYP enzymes
- Clinically important human phase I CYP isozymes
- CYP2C19 pharmacogenetics
- Psychotropic drugs metabolized by CYP2D6
- Human CYP2D gene cluster
- CYP2D6 genetic variants
- Debrisoquine and CYP2D6 genetic polymorphism
- Nortriptyline: an excellent example
- Fluoxetine N-demethylation by CYP2D6 isoforms
- CYP2D6 polymorphism: inter-ethnic difference
- Debrisoquine phenotype: inter-ethnic difference
- CYP2D6 polymorphism and drug inactivation
- CYP2D6 polymorphism and prodrug activation
- Metabolism of codeine
- Morphine production in CYP2D6 EMs and PMs
- Pain tolerance in CYP2D6 EMs and PMs
- Codeine intoxication associated with CYP2D6 UM
- CYP2D6 is expressed in human brain
- CYP genetic polymorphism: issues
- CYP genetic polymorphism: opportunity
- Phenotyping towards individualized drug therapy
- Genotyping towards individualized drug therapy
- CYP2D6 genotyping towards individualized therapy
- Genotyping/phenotyping methods: comparison
- Phenotyping vs. genotyping: pros and cons
- Potency of CYP2D6 inhibitor
- Drug-drug interactions altered CYP2D6 activity
- CYP2D6 polymorphism: psychopharmacotherapy
- References
Topics Covered
- Inter-patient variations caused by Phase I drug metabolizing enzymes
- Genetic polymorphism of CYP2D6 and impact on psychopharmacotherapy
- Metabolism, pharmacokinetics, pharmacodynamics and toxicity
- Pharmacogenetics and pharmacogenomics move towards individualized drug therapy
Links
Series:
Categories:
Talk Citation
Yu, A. (2007, October 1). Genetics of phase I enzymes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/HEZV1564.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Aiming Yu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.